Answers are grounded in this paper and cite their sources.
Background/Objectives: Chronic central serous chorioretinopathy (cCSC) is a challenging retinal condition characterized by persistent neurosensory retinal detachment and subretinal fluid lasting beyond six months, which can lead to irreversible visual impairment. Current treatment options have limitations and more effective therapeutic approaches are needed. Brolucizumab, a humanized single-chain antibody fragment with the smallest molecular weight among anti-VEGF agents, may offer advantages. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of intravitreal brolucizumab for cCSC. Methods: We conducted a comprehensive literature search across PubMed, Google Scholar, ScienceDirect, and Scopus through April 2026, following PRISMA guidelines. We included studies evaluating intravitreal brolucizumab in patients with confirmed cCSC. The primary outcomes were the mean differences (MD) in best-corrected visual acuity (BCVA), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) before and after treatment. Secondary outcomes included the proportion for resolution of subretinal fluid (SRF), intraretinal fluid (IRF), and pigment epithelial detachment (PED). A random-effects model was used for all pooled analyses. We assessed risk of bias using the Cochrane RoB-2 tool and National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool for Pre–Post Studies with No Control Group and evaluated evidence certainty using the GRADEpro GDT web-based tool. Results: A total of seven studies, comprising 113 eyes, were included in this study. Pooled analysis using a random-effects model showed significant improvement in BCVA (MD = −0.15; 95% CI: −0.21 to −0.09; p < 0.01), with significant reductions in CMT (MD = −124.11; 95% CI: −147.26 to −100.97; p < 0.01), and SFCT (MD = −60.17; 95% CI: −93.53 to −26.81; p < 0.01). Brolucizumab resolved the SRF at a proportion of 83.0% (95% CI: 61.0 to 94.0), PED at a proportion of 55.0% (95% CI: 19.0 to 87.0), and IRF at a proportion of 59.0% (95% CI: 0.0 to 100.0) following a random-effect model. Safety analysis showed only one case of mild self-limited vitritis, with no reports of retinal vasculitis or vascular occlusion across all studies. All outcomes were rated to be of very low certainty. Conclusions: Intravitreal brolucizumab showed improvements in both visual and anatomical outcomes in patients with cCSC. However, the evidence and safety profile are limited by the small number of predominantly observational studies, variable follow-up duration, and overall very low certainty according to GRADE assessment. Large, well-designed randomized controlled trials with extended follow-up are needed to confirm long-term efficacy and safety and establish brolucizumab’s definitive clinical role in cCSC management.
No takes yet. Share an insight, caveat, or question.
Albader et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: